Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT04565457 Suspended - Prostate Cancer Clinical Trials

A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality

Start date: December 1, 2022
Phase: Early Phase 1
Study type: Interventional

This is Pilot study that investigates the CBCT(Cone beam computed tomography) image quality improvement provided by the 2D antiscatter grid technology. The primary objective is to assess the improvement in tissue visualization in an observer study, which will be conducted in a blinded fashion.

NCT ID: NCT04389918 Suspended - Prostate Cancer Clinical Trials

Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

Start date: October 26, 2020
Phase: N/A
Study type: Interventional

This study will find out if a meal replacement of this type is satisfying and tolerable for men with prostate cancer. Participants will receive meal replacements of TalityTM as their expected sole source of nutrition for 4 weeks. The purpose of the study is to test whether TalityTM Synthetic Meal Replacements are suitable to be used in larger studies of patients with prostate or other types of cancer.

NCT ID: NCT04264208 Suspended - Prostate Cancer Clinical Trials

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Start date: February 5, 2020
Phase: Phase 2
Study type: Interventional

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

NCT ID: NCT04176497 Suspended - Prostate Cancer Clinical Trials

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Start date: July 16, 2020
Phase: Phase 2
Study type: Interventional

The goal of this study is to investigate the feasibility and toxicity of using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multi-parametric magnetic resonance imagining (mpMRI) with PET-MR technology to define radiotherapy targets, while meeting all the current planning criteria.

NCT ID: NCT03949517 Suspended - Prostate Cancer Clinical Trials

A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

Start date: April 9, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer.

NCT ID: NCT03862170 Suspended - Prostate Cancer Clinical Trials

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

BRP30
Start date: February 10, 2015
Phase: Phase 3
Study type: Interventional

Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.

NCT ID: NCT03809078 Suspended - Prostate Cancer Clinical Trials

A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Start date: January 14, 2019
Phase: Phase 2
Study type: Interventional

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

NCT ID: NCT03734575 Suspended - Prostate Cancer Clinical Trials

ClariCore System Used in Transperineal Prostate Biopsy

Start date: October 10, 2018
Phase: N/A
Study type: Interventional

The overall objective of this study is to acquire ultrasound images, spectral data and prostate tissue biopsy cores using the ClariCore System via a transperineal approach.

NCT ID: NCT03694483 Suspended - Prostate Cancer Clinical Trials

Prostasomes as Diagnostic Tool for Prostate Cancer Detection

Start date: October 3, 2018
Phase:
Study type: Observational

Prostate cancer is the most frequently diagnosed cancer among men over 50 years old in Western societies, with an incidence that is steadily increasing in most countries. The current, most commonly used biomarker for prostate cancer is prostate specific antigen (PSA), which has well known limitations in accuracy and requires additional testing. However, prostate cancer cells secrete exosomes, also known as prostasomes, which are only detectable in the blood of prostate cancer patients. The presence of prostasomes in the blood is in itself a prostate cancer diagnosis. However, the assay that has been designed for the purification of prostasomes requires additional testing for evaluating its robustness and usefulness in the clinical setting. Additionally, the evaluation of the cargo of the purified prostasomes may provide more information on the nature of the prostate cancer, which may help develop a molecular assay for a prostate cancer liquid biopsy rather than a tissue biopsy. Therefore, the purpose of this study is two-fold: a validation phase where the purification of prostasomes will be tested on plasma collected from prostate cancer patients and a molecular testing phase where the contents of the purified prostasomes will be evaluated on their ability to determine the grade of the prostate tumors. We will collaborate with Dr. Masood Kamali-Moghaddam at the Uppsala University (Department of Immunology, Genetics and Pathology) for molecular assay processing.

NCT ID: NCT03574194 Suspended - Breast Cancer Clinical Trials

Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy

Start date: June 12, 2018
Phase: N/A
Study type: Interventional

A diet consisting of a reduced quantity of the essential amino acid methionine sensitizes cancer cells to radiation therapy and reduces metastasis formation and disease progression in mice. However, to date, dietary restriction of methionine has not been tested in combination with radiation therapy in humans as a strategy to improve patient outcomes.